What ratio of cagrilintide to semaglutide is in each vial?

Name: Cagrisema
Price: 95 USD
Availability: InStock

Each vial contains equal quantities of both peptides. For example, a 10mg vial contains 5mg cagrilintide and 5mg semaglutide. Dosing in clinical research used 2.4mg of each component administered together once weekly.

Cagrisema

Pre-formulated combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Phase 2 data showed 15.6% weight reduction with a favourable

Fat LossGH Boost

● In Stock

Select Variant

Quantity (vials)

Buy more, save more

—

1+ vials

−5%

3+ vials

−10%

5+ vials

−20%

10+ vials

Total Price

$95

For research & laboratory use only. Not for human consumption.

Half-Life

7 days (both components)

Administration Route

Subcutaneous injection

Dual Hormone Mimicry

Combines amylin (cagrilintide) + GLP-1 (semaglutide) action

15.6% Weight Loss

Phase 2 SCALE trial at 32 weeks, exceeds monotherapy

Reduced Side Effects

Amylin component buffers GLP-1 GI effects

Effect Profile

Based on primary research mechanisms

Fat Loss

Hunger Control

Metabolic Health

Energy

Mechanism of Action

CagriSema combines cagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) in a single formulation. The two compounds act through distinct receptor systems: semaglutide reduces appetite and slows gastric emptying via hypothalamic and brainstem GLP-1 receptors, while cagrilintide acts on brainstem amylin receptors to independently promote satiety and suppress post-prandial glucagon. The combination of complementary pathways produces additive weight reduction greater than either agent alone.